As Echinacea, Ginseng, St. John's Wort and other nutritional supplements come under fire, the recent M&A activity fueled by their popularity may wane. Earlier in February, New York Attorney General  Eric Schneiderman ordered GNC Holdings  Inc. (NYSE: GNC), Target Corp. (NYSE: TGT), Wal-Mart Stores Inc. (NYSE: WMT) and Walgreens Inc. (NYSE: WAG) to stop selling store-brand herbal supplements after DNA tests showed a whopping 79 percent of the supplements at select New York stores did not contain the key ingredient advertised, or were contaminated with other materials.

Laura Nolan, vice president at Little Rock, Arkansas-based investment bank Stephens Inc., advises on consumer and retail deals and is an expert on the better-for-you category. We asked Nolan about how the  scandal will affect transactions in the vitamins, minerals and supplements (VMS) sector.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.